Fig. 2.

Flow chart with the treatment options in severe and life-threatening bleeding events. (CHA₂DS₂-VASc congestive heart failure, hypertension, age ≥75 [doubled], diabetes, prior stroke [doubled]—vascular disease, age 65–74, sex category, DAPT dual antiplatelet therapy, INR international normalised ratio, OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K oral anticoagulant, SAPT single antiplatelet therapy, PPI proton pump inhibitor, GI gastrointestinal, RBC red blood cell, Hb haemoglobin, FFP fresh frozen plasma, 4F-PCC four factors prothrombin complex concentrates, i. v. intravenous. *Mechanical heart valve, cardiac assist device, CHA₂DS₂-VASc score ≥4. **Mechanical heart valve, cardiac assist device. ***Mechanical heart valve in mitral position, cardiac assist device)